Evelo Biosciences, Inc. (NASDAQ:EVLO – Get Free Report) was the target of some unusual options trading on Wednesday. Stock investors acquired 1,885 put options on the company. This is an increase of 1,101% compared to the average daily volume of 157 put options.
Institutional Investors Weigh In On Evelo Biosciences
A number of institutional investors have recently modified their holdings of EVLO. Shay Capital LLC acquired a new stake in shares of Evelo Biosciences in the fourth quarter valued at $30,000. Barclays PLC grew its stake in Evelo Biosciences by 654.2% during the 4th quarter. Barclays PLC now owns 22,641 shares of the company’s stock worth $36,000 after purchasing an additional 19,639 shares in the last quarter. Walleye Capital LLC acquired a new position in Evelo Biosciences during the 1st quarter worth $38,000. Boothbay Fund Management LLC acquired a new position in Evelo Biosciences during the 4th quarter worth $85,000. Finally, Man Group plc acquired a new position in Evelo Biosciences during the 4th quarter worth $85,000. 0.31% of the stock is owned by institutional investors and hedge funds.
Evelo Biosciences Stock Performance
Shares of NASDAQ EVLO opened at $0.04 on Thursday. Evelo Biosciences has a twelve month low of $0.03 and a twelve month high of $13.93. The stock has a fifty day simple moving average of $0.05 and a 200-day simple moving average of $0.43. The stock has a market capitalization of $834,171.00, a PE ratio of 0.00 and a beta of 2.03.
Evelo Biosciences Company Profile
Evelo Biosciences, Inc, a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis.
Further Reading
- Five stocks we like better than Evelo Biosciences
- How to Effectively Use the MarketBeat Ratings Screener
- United Airlines Soars on Earnings Beat
- Russell 2000 Index, How Investors Use it For Profitable Trading
- J.B. Hunt Hits the Skids: Lower Prices to Come
- Why Invest in High-Yield Dividend Stocks?
- Predicting a Bear Market: 7 Signs and Why it’s Tough to Do
Receive News & Ratings for Evelo Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evelo Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.